<DOC>
	<DOCNO>NCT00186745</DOCNO>
	<brief_summary>Blood clot leg vein , know deep vein thrombosis , important may travel lung ( know pulmonary embolism ) cause death . Blood clot treat blood thinner , anticoagulant . The preferred treatment anticoagulant know low molecular weight heparin ( LMWH ) . LMWH give injection skin , convenient patient self-administer medication home , blood testing require . However , LMWH clear body kidney , patient kidney failure generally treat LMWH may higher risk bleed . One type LMWH , know tinzaparin , may less dependent kidney clearance may increase patient kidney failure . The investigator would like use tinzaparin treat patient deep vein thrombosis pulmonary embolism , also kidney failure . The purpose study determine whether blood thin effect tinzaparin build , accumulate , patient vary degree kidney failure compare patient without kidney failure . The blood thin effect measure use blood test know anti-Xa level . Patients follow time receive tinzaparin patient find potentially high level tinzaparin ( base anti-Xa level ) tinzaparin dose adjust . The investigator believe level tinzaparin accumulate potentially dangerous level significant number patient kidney failure .</brief_summary>
	<brief_title>Use Low Molecular Weight Heparin ( Tinzaparin ) Treat Blood Clots Patients With Kidney Failure</brief_title>
	<detailed_description>Background rationale . Venous thromboembolism ( VTE ) important clinical problem common , preventable , contribute morbidity mortality , costly . Low molecular weight heparin ( LMWH ) prefer anticoagulant VTE treatment , renally excrete . Consequently , LMWH use patient renal insufficiency may result accumulation anticoagulant effect potential avoidable bleeding complication . As result , patient renal insufficiency also VTE unable benefit LMWH treatment . These patient therefore generally treat hospital use unfractionated heparin ( UFH ) , since eliminate extra-renal mechanism . In addition patient know renal insufficiency , many elderly patient previously unrecognized renal insufficiency treatment patient LMWH associate accumulation anticoagulant effect avoidable bleeding . Tinzaparin , relative LMWHs , high molecular weight great negative charge : biochemical feature favour non-renal clearance . There limited evidence support hypothesis tinzaparin , unlike LMWHs , accumulate patient renal insufficiency . 1 ) Observational study demonstrate increase anti-Xa level ( i.e. , accumulation ) tinzaparin use VTE treatment elderly patient renal insufficiency . 2 ) One study show undetectable LMWH anticoagulant activity 24 hour dose hemodialysis patient . 3 ) A systematic review meta-analysis literature area perform research group find difference bleed thrombosis complication rate LMWH ( compare UFH ) use maintain dialysis circuit patency patient hemodialysis . The current factor limit use tinzaparin treatment patient VTE renal insufficiency : 1 ) true risk accumulation unknown spectrum patient vary renal function , 2 ) bleeding risk associate tinzaparin use unknown . Hypothesis . We hypothesize accumulation 5-day course tinzaparin related degree renal insufficiency . Study design method . We perform prospective cohort study 200 patient acute VTE , stratify 4 equal-sized group renal function , receive initial anticoagulation tinzaparin 5 day concurrent oral anticoagulant . The LMWH anticoagulant effect assess day 3 5 ( +/- 1 ) use trough anti-Xa heparin level . If accumulation occur , define trough anti-Xa level &gt; 0.5 IU/mL , tinzaparin dose adjust accord nomogram . Patients anti-Xa level â‰¤ 0.5 IU/mL dose adjustment ; patient level &gt; 0.5 IU/mL tinzaparin dose reduce . The primary outcome study proportion patient renal function group accumulation day 5 . We follow patient 48 hour final tinzaparin injection . Secondary outcome bleed , recurrent thrombosis , accumulation day 3 , trough anti-Xa level &gt; 1.0 IU/mL point study . Significance . We hypothesize tinzaparin accumulate patient renal insufficiency . However , accumulation occurs , hypothesize dose adjustment accord novel nomogram prevent potentially-dangerous level occur day 5 . In either case , able proceed next stage research plan : application fund large simple randomize controlled trial examine safety efficacy tinzaparin compare UFH patient renal insufficiency . If accumulation occur despite use nomogram , surrogate outcome suggest use therapeutic-dose tinzaparin unlikely safe patient renal insufficiency , find limit need expend resource line research .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<criteria>Adult patient 18 year age older Objectively confirm VTE require anticoagulant therapy , include low extremity upper extremity deep vein thrombosis ( catheter noncatheter relate , include dialysis access thrombosis [ i.e. , graft , fistula ] ) ; peripheral vein thrombosis ( e.g. , portal vein , mesenteric vein , cerebral vein thrombosis ) , pulmonary embolism Weight exceed 105 kg Unstable decline renal function , define documented change creatinine &gt; 20 % past 3 month clinical circumstance likely associate change renal function , dehydration severe intercurrent illness . Where previous creatinine value exist patient otherwise stable , patient exclude basis unknown previous renal function . Known allergy heparin/LMWHs history heparin induce thrombocytopenia Treatment UFH , LMWH , danaparoid , oral direct thrombin inhibitor &gt; 48 h Bleeding require hospitalization blood transfusion within 6 month ( exception blood transfusion give relation surgical procedure within 6 month ) History intracerebral hemorrhage Known active liver disease ( AST ALT &gt; 3 time upper limit normal , bilirubin &gt; 50 umol/L ) Known active peptic ulcer disease , ongoing symptom need antiulcer medical therapy Thrombocytopenia ( platelet count &lt; 100 x 109/L ) Ongoing need antiplatelet agent ( clopidogrel , ticlopidine , aspirin &gt; 325 mg daily ) Pregnancy lactation Geographic inaccessibility Unable , unwilling , provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Venous thrombosis</keyword>
	<keyword>Pulmonary embolism</keyword>
	<keyword>Kidney failure</keyword>
	<keyword>Anticoagulants</keyword>
	<keyword>Heparin , Low-Molecular-Weight</keyword>
</DOC>